Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells?

Moll, Guido; Hult, Annika; von Bahr, Lena; Alm, Jessica J; Heldring, Nina; Hamad, Osama A; Stenbeck-Funke, Lillemor; Larsson, Stella; Teramura, Yuji; Roelofs, Helene; Nilsson, Bo; Fibbe, Willem E; Olsson, Martin L; Le Blanc, Katarina

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0085040

2014

Link to publication

Citation for published version (APA):
Moll, G., Hult, A., von Bahr, L., Alm, J. J., Heldring, N., Hamad, O. A., ... Le Blanc, K. (2014). Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells? PLoS ONE, 9(1), [e85040]. https://doi.org/10.1371/journal.pone.0085040

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Introduction

MSCs are tested in a large number of clinical trials with focus on exploiting their regenerative and immune modulatory properties [1–3]. The treatment is safe [3,4], but efficacy of the first generation product is low [3], with an average clinical response rate of 68% at its latest follow up [5]. We have worked on identifying potential predictors of improved outcome, such as better patient stratification, use of early passage cells [6], and general improvements in blood compatibility of the product [7]. We here study the possible impact of immunogenic ABO antigens on the outcome of MSC therapy, from ex vivo preparation, to cell infusion, and consecutive patient response evaluation.

The ABO blood group is one of the major immunogenic barriers hampering tissue transplantation into immunocompetent hosts [8]. ABO donor blood groups are therefore readily available from hospital routine assessment without increased costs. The clinical MSCs could either display intrinsic ABO antigen expression according to their genetic determinants, or be externally contaminated. Carbohydrate blood groups are not encoded by genes directly, but blood group genes encode glycosyltransferases that synthesize the oligosaccharide epitopes [9]. Thus A/B antigens are added to the H core structure by A/B glycosyltransferases, encoded by the ABO gene. Methylation of the ABO proximal promoter is associated with down-regulation of A/B transcripts in hematological malignancy [10], and down-regulation can also be found in tumors compared to normal tissue [11].Transient depression in A antigen expression has also been observed in pregnancy [12]. The specific reasons for conditional ABO promoter methylation remain elusive, but down-modulation of blood group antigens appears to be associated with classical states/sites of immune privilege [9].

Abstract

Investigation into predictors for treatment outcome is essential to improve the clinical efficacy of therapeutic multipotent mesenchymal stromal cells (MSCs). We therefore studied the possible harmful impact of immunogenic ABO blood group antigens – genetically governed antigenic determinants – at all given steps of MSC-therapy, from cell isolation and preparation for clinical use, to final recipient outcome. We found that clinical MSCs do not inherently express or upregulate ABO blood group antigens after inflammatory challenge or in vitro differentiation. Although antigen adsorption from standard culture supplements was minimal, MSCs adsorbed small quantities of ABO antigen from fresh human AB plasma (ABP), dependent on antigen concentration and adsorption time. Compared to cells washed in non-immunogenic human serum albumin (HSA), MSCs washed with ABP elicited stronger blood responses after exposure to blood from healthy O donors in vitro, containing high titers of ABO antibodies. Clinical evaluation of hematopoietic stem cell transplant (HSCT) recipients found only very low titers of anti-A/B agglutination in these strongly immunocompromised patients at the time of MSC treatment. Patient analysis revealed a trend for lower clinical response in blood group O recipients treated with ABP-exposed MSC products, but not with HSA-exposed products. We conclude, that clinical grade MSCs are ABO-neutral, but the ABP used for washing and infusion of MSCs can contaminate the cells with immunogenic ABO substance and should therefore be substituted by non-immunogenic HSA, particularly when cells are given to immunocompetent individuals.

Citation: Moll G, Hult A, Bahr Lv, Alm JJ, Heldring N, et al. (2014) Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells? PLoS ONE 9(1): e85040. doi:10.1371/journal.pone.0085040

Editor: Pranela Rameshwar, Rutgers - New Jersey Medical School, United States of America

Received October 10, 2013; Accepted November 19, 2013; Published January 13, 2014

Copyright: © 2014 Moll et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants from the Swedish Cancer Society (11 0315), the Children’s Cancer Foundation (PROJ11/034), the Swedish Medical Research Council (K2011-78X-20742-04-6), VINNOVA (2010-00501), the Stockholm County Council (ALF) (20110152), the Cancer Society in Stockholm, the Swedish Medical Research Council/ VINNOVA/ Swedish Foundation Strategic Research (6076170), the Juvenile Diabetes Foundation International, and the NIH (2U01AI 065192-06) (to W.E.F.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: guido.moll@ki.se

Introduction

MSCs are tested in a large number of clinical trials with focus on exploiting their regenerative and immune modulatory properties [1–3]. The treatment is safe [3,4], but efficacy of the first generation product is low [3], with an average clinical response rate of 68% at its latest follow up [5]. We have worked on identifying potential predictors of improved outcome, such as better patient stratification, use of early passage cells [6], and general improvements in blood compatibility of the product [7]. We here study the possible impact of immunogenic ABO antigens on the outcome of MSC therapy, from ex vivo preparation, to cell infusion, and consecutive patient response evaluation.

The ABO blood group is one of the major immunogenic barriers hampering tissue transplantation into immunocompetent hosts [8]. ABO donor blood groups are therefore readily available from hospital routine assessment without increased costs. The clinical MSCs could either display intrinsic ABO antigen expression according to their genetic determinants, or be externally contaminated. Carbohydrate blood groups are not encoded by genes directly, but blood group genes encode glycosyltransferases that synthesize the oligosaccharide epitopes [9]. Thus A/B antigens are added to the H core structure by A/B glycosyltransferases, encoded by the ABO gene. Methylation of the ABO proximal promoter is associated with down-regulation of A/B transcripts in hematological malignancy [10], and down-regulation can also be found in tumors compared to normal tissue [11]. Transient depression in A antigen expression has also been observed in pregnancy [12]. The specific reasons for conditional ABO promoter methylation remain elusive, but down-modulation of blood group antigens appears to be associated with classical states/sites of immune privilege [9].
Clinical MSCs could also be contaminated with ABO antigens from culture supplements, and washing buffers, used for cell infusion. Antigens showing cross-reactivity with ABO antibodies are potentially found in animal components [6], such as fetal calf serum (FCS) [13], and its human substitutes, such as pooled human AB serum (ABS) and platelet rich plasma (PRP) [14–17]. Prior studies indicated that ABO antigens are not expressed in native or in vitro differentiated MSCs and not adsorbed from culture medium [18,19]. Antigen adsorption from AB plasma (ABP), which is often used for washing and infusion of MSCs, was not investigated. Prior studies further suggested human serum albumin (HSA) as a non-immunogenic supplement [20]. Differences in antigenicity exist for human donor sera/plasmas with respect to variation in antibody and soluble antigen content, and secretor status [9]. Classically, human blood group AB serum/plasma is considered to be the most reasonable choice for avoiding harmful reactions, due to its lack of ABO antibodies [16]. However, highly immunogenic soluble A and B antigens can be present [9], which could potentially be adsorbed to clinical grade MSCs. Transplant patients receiving ABO-incompatible grafts may show three types of immune response to incompatibile A/B antigens: 1) Rejection, 2) Accommodation, and 3) Tolerance [9]. It is unclear whether preformed naturally-occurring antibodies can impair the therapeutic efficiency of MSCs. In solid organ transplantation it was documented that particularly adult blood group O recipients constitute a risk group for early allograft rejection, due to higher titers of anti-A/B immunoglobulin G (IgG) antibodies [21].

Here, we have investigated the ABO-related therapeutic efficiency of MSCs, totaling a number of more than 100 cell infusions at our two centers. We first characterized the ABO-antigen status of the native therapeutic product and then analyzed the therapeutic outcome with respect to donor – recipient ABO status.

Materials and Methods

MSC Recipients and ethics statement

HSCT recipients from the Karolinska University Hospital (n = 48) and Leiden University Hospital (n = 25), who received treatment with MSCs between 2002 and 2011, were included in the analysis. The patients received myeloablative (n = 40) or reduced intensity (n = 33) conditioning and routine graft-versus-host disease (GvHD) prophylaxis according to previously published procedures and patient outcome has been included in previous reports [5,6,22]. The patients received 1–5 infusions of MSCs, (median 1 infusion) and 105 infusions were included in the analysis. All response data are presented as per infusion. The indications for MSC treatment were acute GvHD (83 infusions) or host disease (GvHD) prophylaxis according to previously published procedures and patient outcome has been included in previous reports [5,6,22]. The patients received myeloablative (n = 40) or reduced intensity (n = 33) conditioning and routine graft-versus-host disease (GvHD) prophylaxis according to previously published procedures and patient outcome has been included in previous reports [5,6,22]. The patients received 1–5 infusions of MSCs, (median 1 infusion) and 105 infusions were included in the analysis. All response data are presented as per infusion. The indications for MSC treatment were acute GvHD (83 infusions) or hemorrhagic cystitis (22 infusions). The MSCs were obtained from HLA-identical siblings (n = 3), haploidentical donors (n = 12) or 3rd party unrelated donors (n = 90). They were given in passage 1 – 4 (median 3) and in a median dose of 1.7×10^6 cells/kg (range 0.7 – 4.2×10^6 cells/kg). For rapid availability, most of the cells were stored in liquid nitrogen and freshly thawed for IV infusion (n = 96) and some patients received one infusion each of freshly detached cells (n = 9). Donors and patients or their legal guardians gave written informed consent and the review board at Karolinska University Hospital Huddinge approved the study. All clinical research was conducted according to the principles expressed in the Declaration of Helsinki.

ABO blood group typing of patients and ABO antibody titer in patient blood

ABO grouping including detection of anti-A and anti-B titers in patient blood was done by automated serological tests at the hospital site based on the micro-column technique and by agglutination of erythrocytes of known blood group.

Isolation and preparation of therapeutic MSCs

To isolate MSCs, bone marrow aspirates of approximately 50 ml were taken from the iliac crest of healthy donors (n = 50; median age 37; range 6 – 68 years). The expansion and characterization of the MSCs was performed according to the guidelines of the MSC Consortium of the European Blood and Marrow Transplantation Group (EBMT) and approved by the Swedish National Board of Health and Welfare, as previously described in detail [5,23,24]. Briefly, bone marrow mononuclear cells were separated over a gradient of Redigrad (GE Health Care, Sweden), washed and resuspended in DMEM low-glucose medium (DMEM-LG; Invitrogen, Grand Island, NY); supplemented with 100 IU/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS (Hyclone, Logan, Utah, USA), or alternatively 5% human ABS or PRP, and plated at 1.6×10^3 cells/cm². When the cultures approached confluence (>80%), the cells were detached by treatment with trypsin and EDTA (Invitrogen, Grand Island, NY) and replated/passaged at a density of 4.0×10^3 cells/cm² for up to four passages. Flow cytometry analysis indicated that the MSCs were positive for CD73, CD90 and CD105 but negative for CD14, CD31, CD34 and CD45. Adipogenic and osteogenic differentiation was evaluated as previously described [23]. The MSC suspensions were culture-negative for bacteria and fungi and polymerase chain reaction (PCR)-negative for Mycoplasma [5,24].

ABO genotype, promoter methylation, and transcript analysis on clinical MSCs

**ABO and FUT2 genotyping.** Two independent methods for determination of ABO genotyping were performed on DNA prepared from thawed clinical grade MSCs at the Nordic Reference Laboratory for Genetic Blood Group Typing at the University and Regional Laboratories in Lund, Sweden. These included an allele-specific primer (ASP) PCR [25] and a restriction fragment length polymorphism (RFLP) PCR [26] FUT2 genotyping was performed with an unpublished method developed in house, assessing nucleotide position 428 (G/A) to determine secretor vs. non-secretor status.

**ABO promoter methylation status.** The promoter methylation status was analyzed with MagMeDIP Kit (mc-magme-048; Diagenode, Belgium) according to manual. Briefly, DNA was isolated from MSCs (n = 4) and 1 μg sonicated DNA was used. Methylated DNA positive control and unmethylated DNA negative control were spiked into one sample in order to control for the assay. Sonicated DNA was added to two tubes: input DNA (10% of sonicated DNA) and immunoprecipitation (IP) sample DNA. IP incubation mix was added to both tubes, heated at 95°C for three minutes and briefly centrifuged at 4°C. The 10% input DNA samples were then stored at 4°C. The provided anti-5mC antibody was diluted 1:2 in water before making the antibody mix with MagBuffer A and C and added to the IP tubes. Magbeads (11 μl/IP) were washed and resuspended in bead wash buffer before added to the IP's. The samples were incubated at 4°C over night. The DNA samples were washed three times with 100 μl ice-cold MagWash Buffer-1 and ice-cold MagWash Buffer-2. After the last wash, the last traces of Wash buffer were discarded. The bead pellets were kept on ice. Input samples were centrifuged briefly...
and from this point on treated in parallel with IP samples. DNA isolation buffer (DB) was prepared adding 1 μL of Proteinase K per 100 μL of DB. The tubes were removed from the Magnetic Rack and complete DB was added to each sample and incubated at 55°C for 15 min and then at 100°C for 15 min. The samples were then centrifuged at 14,000 rpm for 5 min at 4°C and supernatants analyzed in a SYBR green Q-PCR assay using ABO promoter-specific primers: FW; CCGTTGACACCCCTGTCTCC REV; AGCTTCACGGGTCTGCTTG. Primers for the methylated promoter (TSH2B) and the unmethylated promoter (GAPDH) were provided in the kit.

**ABO transcript analysis.** To study mRNA transcripts in resting or stimulated cells, MSCs were subjected to standard differentiation or pro-inflammatory mediators. Adipogenic and osteogenic differentiation was induced [23], and confirmed by lipid vacuole formation/upregulation of gene aP2, and matrix mineralization, respectively. To activate MSCs with cytokines, the cells were exposed for 5 days either to 100 U/ml recombinant human interferon gamma (IFNg; Sigma Aldrich Ltd, UK), or to pro-inflammatory mediators secreted by activated PBMCs in trans-well mixed lymphocyte reactions (MLRs), and harvested for transcript analysis as described earlier [7]. Cell lysates were harvested with RLT buffer (Qiagen, Hilden, Germany), RNA was extracted using a Qiagen RNeasy minikit, and stored in RNase-free water at −80°C. Concentration and purity of RNA was estimated by reading absorbance at 260 and 280 nm with a spectrophotometer (Nanodrop; Thermo Fisher, Wilmington, DE). The cDNA samples used for PCR analysis were obtained with the high-capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). QRT-PCR analysis was performed with the Applied Biosystems 7900 HT sequence detection system. The Foster City, CA). QRT-PCR analysis was performed with the Applied Biosystems 7900 HT sequence detection system. The sample volume used for PCR analysis was obtained with the Applied Biosystems 7900 HT sequence detection system. The sample volume used for PCR analysis was obtained with the Applied Biosystems 7900 HT sequence detection system. The sample volume used for PCR analysis was obtained with the Applied Biosystems 7900 HT sequence detection system. The expression of beta-actin served as an internal standard: \( Ct = Ct(Gene) \), with \( Ct \) being the cycle threshold of beta-actin and from this point on treated in parallel with IP samples. DNA isolation buffer (DB) was prepared adding 1 μL of Proteinase K per 100 μL of DB. The tubes were removed from the Magnetic Rack and complete DB was added to each sample and incubated at 55°C for 15 min and then at 100°C for 15 min. The samples were then centrifuged at 14,000 rpm for 5 min at 4°C and supernatants analyzed in a SYBR green Q-PCR assay using ABO promoter-specific primers: FW; CCGTTGACACCCCTGTCTCC REV; AGCTTCACGGGTCTGCTTG. Primers for the methylated promoter (TSH2B) and the unmethylated promoter (GAPDH) were provided in the kit.

Flow cytometry detection of ABH antigens on MSCs cultured with different supplements and antigen adsorption from human AB plasma

A highly sensitive flow cytometry assay for detection of low levels of ABH histo-blood group antigens, previously developed for quality control of blood group A, B and AB red blood cells (RBCs) converted to type as group O was applied [28]. Its sensitivity was confirmed by detection of A antigen on RBCs of the weakly expressing, inherited Ax subgroup and also detection of the minute levels of A antigens present on group B RBCs. Paragloboside carbohydrate antigen served as positive control for secondary antibody binding, blood group O MSCs served as negative controls for anti-A and -B detection, and MSCs labeled with secondary antibody only were used as baseline values. To detect antigen adsorption from culture supplements, cells were isolated and expanded in the presence of 10% FCS, 5% ABS, or 5% PRP, as described above. Additionally, adsorption of blood group A/B-antigen from fresh clinical ABP, used as supplement for washing, reconstitution and clinical infusion of MSCs, was tested. Clinical MSC preparations were thawed, briefly washed in buffer containing 10% O plasma to remove DMSO from cryo-medium, then resuspended in a small volume of PBS, and aliquoted in FACs tubes for incubation with different types of plasmas for either 1 or 3 hours. As positive control for A/B-antigen adsorption MSCs were incubated with 100% A,B, and A2,B plasma and as a negative control with 100% O non-secretor plasma (200,000 MSCs were incubated with 0.5 ml of undiluted plasma or with 2 ml PBS containing 10% plasma). Anti-A/B detection was performed on washed cells as described above. Additionally, MSCs were labeled with the PE-conjugated isotype control and positive (CD105-PE) or negative (CD14-PE) control antibodies. All antibodies are listed in Table S1.

Whole blood exposure of fresh and thawed MSCs washed and resuspended in buffer containing either 10% ABP or HSA

Fresh or thawed MSCs were washed and resuspended in buffer containing either 10% ABP or HSA and exposed to blood by using the Chandler loop system, consisting of tubing with a heparinized inner surface (Corline Systems), as described previously [7,29–31]. Fresh non-anti-coagulated blood group O donor blood was obtained from healthy volunteers who had given informed consent in accordance with the Helsinki Protocol and had received no medication for at least 10 days [7]. Briefly, pieces of tubing containing 7 ml of blood were prepared and supplemented with 100 μl of PBS containing 10% ABP or HSA +/- freshly detached or freeze-thawed MSCs. To determine the time course of reaction between blood and cells 1-ml samples from each blood tube were collected before cell addition and at 5, 15, 30, and 60 min after cell addition. Reactions were stopped by the addition of EDTA (pH 7.4, 10 mM final). Platelet and cell counts were obtained by using a cell counter (Beckman Coulter). The remaining sample volume was centrifuged at 3000 g for 20 min at 4°C. Plasma was collected, stored at −80°C, and formation of thrombin-anti-thrombin complex (TAT) and complement C3 activation fragment a (C3a) was measured by ELISA [7].

**Statistical analysis**

Statistical analyses were performed using ANOVA and Student’s t-test. If the data did not fit a normal distribution, the Mann-Whitney or the Wilcoxon matched-pairs tests were used (two-tailed confidence intervals, 95%; P<0.05 was considered statistically significant; Prism 5.0; Graphpad Software). For clinical response, differences between responders and non-responders were evaluated using Fisher’s exact test, or when appropriate, Chi2-test.

**Results**

Native clinical MSCs do not express or upregulate ABO blood group antigens

The ABO and FUT2 (secretor) genotypes of 26 clinical MSCs (cultured with 10% FCS) of unknown blood group were determined and their ABH histo-blood group phenotypes predicted (Table 1) [25,26]. We hypothesized that secretor status may play a role in ABH expression and therefore typed for the 428G vs. A polymorphism in the FUT2 gene, associated with secretor vs. non-secretor status, respectively. We found that 85% of tested MSCs had the secretor genotype, i.e. had the genotypes 428G/G or 428G/A. Flow cytometry testing with monoclonal anti-A, -B, and -H confirmed our earlier results [18], that A and B antigens are not expressed on the surface of freshly thawed clinical grade MSCs (Figure S1A), irrespective of their donor secretor status (Figure S1B). Weak positivity was found for the H antigen and strong positivity for the paragloboside positive control (not shown), confirming that these carbohydrate antigens are detectable even after trypsin treatment. We wondered if transcription of the ABO promoter region is silenced in MSCs by DNA methylation (Figure 1A) and found that the promoter is methylated to a similarly low degree as housekeeping gene GAPDH (P<0.001; GAPDH 5% vs. met-TSH2B 90%). We tested if stimulation of MSCs could induce expression of ABO
transcripts in selected cells with known ABO and secretor genotype (K16- A1/Se/se and K25-B/ O1se/Se). None of the treatments (INF-gamma, MLRs, and adipogenic or osteogenic induction) resulted in up-regulation of ABO transcripts (Figure 1B); although the MSCs responded appropriately with up-regulation of control gene ICAM1, p21, formation of lipid vacuoles, and matrix mineralization, respectively. As a positive control, we included the pancreatic adenocarcinoma cell line HPAF-II (blood group A Se/Se), which showed high levels of ABO transcripts comparable to control gene GAPDH.

Clinical grade MSCs adsorb small quantities of ABO antigen from human AB serum and plasma, used for culture and infusion of cells, respectively.

We next wondered if ABO antigens could be adsorbed from the culture media used for cells isolation and expansion. Flow cytometry analysis of low passage MSCs cultured with 5% human ABS showed weak reactivity with anti-A/B antibodies (Figure 2A), which did not occur with cells grown in 5% human PRP or cell culture media used for cells isolation and expansion. Flow cytometry analysis detected a weak shift for binding of anti-A/B after incubation with 10% plasma and a strong shift after incubation with 100% A1B or A2B plasma, but not with O plasma. The signal shift increased after 3 hours of incubation (blue line), compared to the 1-hour incubation time point (pink line). Cell quantification confirmed a weak but significant increase for detection of anti-A/B binding upon

| MSC ID | ABO-ASP Genotype | FUT2-ASP Genotype | Predicted Phenotype | anti-A [RFI] | anti-B [RFI] | anti-H [RFI] |
|--------|------------------|-------------------|---------------------|-------------|-------------|-------------|
| K09    | A1O1             | nt. 428A/A (se/se)| A1 non-secretor     | 1.12        | 1.03        | 1.03        |
| K23    | A1A1             | nt. 428A/A (se/se)| A1 non-secretor     | 1.12        | 1.04        | 6.06        |
| K01    | A1O1             | nt. 428G/A (Se/Se)| A1 secretor         | 0.99        | 0.95        | 4.97        |
| K07    | A1A1             | nt. 428G/A (Se/Se)| A1 secretor         | 1.08        | 0.91        | 1.94        |
| K14    | A1O1             | nt. 428G/A (Se/Se)| A1 secretor         | 1.01        | 0.99        | 1.63        |
| K16    | A1A1             | nt. 428G/A (Se/Se)| A1 secretor         | 1.57        | 1.03        | 1.25        |
| K18    | A1A2             | nt. 428G/G (Se/Se)| A1 secretor         | 1.07        | 1.02        | 1.53        |
| K26    | A1O1             | nt. 428G/G (Se/Se)| A1 secretor         | 0.97        | 0.97        | 1.88        |
| K28    | A1O1v            | nt. 428G/G (Se/Se)| A1 secretor         | 0.77        | 0.87        | 1.58        |
| Kd050  | A1O1            | nt. 428G/A (Se/Se)| A1 secretor         | 1.16        | 1.14        | 1.36        |
| K06    | A1O1v            | nt. 428G/A (Se/Se)| A1 secretor         | 1.00        | 0.95        | 3.38        |
| K17    | A1O1             | nt. 428G/G (Se/Se)| A1 secretor         | 1.02        | 1.00        | 1.70        |
| K12    | A1B              | nt. 428G/A (Se/Se)| A1B secretor        | 1.25        | 1.05        | 1.17        |
| Kd011  | BO1              | nt. 428A/A (se/se)| B non-secretor      | 1.03        | 0.94        | 1.17        |
| Kd006  | BO1              | nt. 428G/A (Se/Se)| B secretor          | 1.01        | 1.01        | 2.37        |
| K11    | BO1              | nt. 428G/G (Se/Se)| B secretor          | 1.06        | 1.00        | 1.40        |
| K20    | BO1              | nt. 428G/A (Se/Se)| B secretor          | 1.05        | 0.97        | 2.39        |
| K25    | BO1              | nt. 428G/G (Se/Se)| B secretor          | 1.22        | 1.08        | 1.31        |
| K13    | O1O1             | nt. 428G/A (Se/Se)| O non-secretor      | 1.05        | 1.09        | 1.20        |
| K05    | O1O1v            | nt. 428G/G (Se/Se)| O secretor          | 0.99        | 0.99        | 1.32        |
| K15    | O1O1v            | nt. 428G/A (Se/Se)| O secretor          | 0.94        | 0.91        | 1.32        |
| K19    | O1O1v            | nt. 428G/A (Se/Se)| O secretor          | 1.08        | 1.03        | 1.19        |
| K21    | O1O1v            | nt. 428G/A (Se/Se)| O secretor          | 0.98        | 0.97        | 1.50        |
| K22    | O1O1v            | nt. 428G/G (Se/Se)| O secretor          | 1.13        | 1.00        | 1.42        |
| K27    | O1O1v            | nt. 428G/A (Se/Se)| O secretor          | 0.94        | 1.14        | 1.17        |
| K29    | O1O1v            | nt. 428G/A (Se/Se)| O secretor          | 0.94        | 0.96        | 1.72        |
| Average: |                 |                   | 85% secretors       | 1.06        | 1.01        | 1.89        |

The ABO (25,26) and FUT2 (secretor) genotype of MSCs was determined with PCR, the ABH histo-blood group phenotype predicted accordingly, and expression of ABH antigens was detected with flow cytometry. The relative fluorescence intensity (RFI) for binding of anti-A, -B, and –H was calculated by dividing the median fluorescence intensity (MFI) obtained for cells labeled with the corresponding antibody, by the MFI obtained for cells labeled with secondary antibody only. Abbreviations: ABO-ASP, ABO allele-specific primer PCR; FUT2-ASP, fucosyltransferase 2 allele-specific primer PCR (nucleotide 428 polymorphism).

doi:10.1371/journal.pone.0085040.t001

Clinical MSCs are often washed and reconstituted in PBS buffer containing 10% fresh ABP for intravenous infusion. The ABP may contain varying levels of immunogenic soluble ABO antigens. In analogy to the culture serum test, we wondered if these soluble ABO antigens in AB plasma could be adsorbed by MSCs, and consequently recognized by the patients’ anti-A/B antibodies, leading to immune destruction. In a mechanistic approach, we incubated blood group O MSCs in 10% or 100% fresh plasma of known blood groups or clinically used plasmas (A1/2B) of unknown A subgroup (Figure 3A). Flow cytometry analysis detected a weak shift for binding of anti-A/B after incubation with 10% plasma and a strong shift after incubation with 100% A1B or A2B plasma, but not with O plasma. The signal shift increased after 3 hours of incubation (blue line), compared to the 1-hour incubation time point (pink line). Cell quantification confirmed a weak but significant increase for detection of anti-A/B binding upon...
incubation with 10% A1B, A2B, and A1/2B plasma, as compared to O plasma (P < 0.05, Figure 3B). We furthermore found a 3-fold increase of anti-A/B-binding to cells treated with 100% A1B, A2B, and A1/2B plasma after 3 hours of incubation (P < 0.05), compared to 1 hour of incubation, suggesting a time- and dose-dependent adsorption of A and B antigens. Positivity of labeling controls for detection of CD105 (95% positive) and paragloboside (60% positive) did not change with time, whilst positivity for negative control CD14 was negligible over the course of incubation.

Washing of MSCs with ABP-containing buffer triggers stronger IBMIR responses in vitro and is associated with a trend for lower response in blood group O recipients in vivo

To verify if MSCs react differently with human blood – in the presence or absence of soluble ABO antigens in washing buffer – we washed and reconstituted the cells in buffer containing either 10% ABP or HSA and subsequently exposed them to blood from healthy, immunocompetent blood group O donors. Visual clot evaluation showed typical donor variation, but a tendency for stronger clot formation with cells resuspended in 10% ABP, particularly for freshly thawed cells, as predominantly used in the clinic (Figure 4A). Cells resuspended in buffer containing ABP elicited a significantly stronger activation of the clotting cascade, as indicated by stronger reduction of free platelets and increased formation of thrombin, which were both stronger for thawed cells (P < 0.1, P < 0.05 and P < 0.01, Figure 4B). ABP-exposed MSCs showed a trend for increased formation of complement activation marker C3a, but this was only significantly increased for thawed cells (P < 0.05).

We next analyzed the anti-A/B agglutination titers in patient plasma of MSC recipients at a median 3.5 days prior (n = 19) and 14 days post MSC-infusion (n = 10). Anti-A/B titers at MSC
infusion were generally low in our patient cohort (Table 2), and
did not show a significant change 14 days post MSC infusion (data
not shown). As expected, the highest levels of anti-A/B titers were
found in blood group O recipients (n = 9, mean IgM/IgG titer of
anti-A 1:4/1:10 and anti-B 1:6/1:11, respectively), whilst blood
group A/B/AB recipients had almost no detectable anti-A/B titers
(n = 10, mean IgM/IgG titer of anti-A undetectable and anti-B
1:1/1:2, respectively). No correlation between the very low MSC
recipient anti-A/B agglutination titers and clinical response to MSC treatment was found (P < 0.05, Figure S2A and S2B).

Evaluation of clinical responses in patients treated with MSCs showed no difference in response for recipients with blood group O before HSCT procedure, compared to patients with original blood group A, B, or AB (Table 3), when combining ABP-exposed and HSA-exposed MSC products. Interestingly, when performing analysis on patients infused with ABP-exposed MSC products (n = 70), we found a trend for a lower clinical response in O recipients compared to blood group A, B, or AB recipients (P = 0.09, 58% vs. 77%, Table S2).

Figure 3. Adsorption of ABO antigens to MSCs from human AB plasma. MSCs are often washed and reconstituted in human AB plasma when prepared for systemic infusion. We therefore used flow cytometry, in order to detect potential binding of A/B-antigens to freshly thawed blood type O MSCs (n = 4) after incubation with human plasmas of different blood types (n = 3 each). (A) Histogram overlay for detection of soluble A/B-antigen binding from plasma to MSCs after a 1-hour (pink curve) or 3-hour (blue curve) incubation with 10% or 100% O, A, B, A1B, or clinical A1/B plasma of unknown A1 or A2 subtype. Upon incubation, cells were washed with serum free media, to remove non-bound plasma components, and A/B-antigen binding was detected with primary mouse-anti-human A/B antibody, followed by incubation with secondary rat-anti-mouse-PE antibody (RAM-PE), and compared to binding of secondary antibody only to untreated cells (black curves). (B) Cells detected positive (%) after two different plasma adsorption times (1 vs. 3 hours). Five AB plasmas of unknowns A subtype, which were previously used for clinical MSC infusion (A12 B), were compared to O, A1B and A2B plasma. As controls, cells were labeled with CD14-PE (negative labeling control), CD105-PE (positive control), and anti-paragloboside (PG) + RAM-PE (secondary antibody labeling control), or anti-A/B + RAM-PE, to detect A/B-antigen binding, as indicated below the figure. Mean ± SD, *P < 0.05.

doi:10.1371/journal.pone.0085040.g003

Discussion

Interpretation of the clinical relevance of ABO blood groups for clinical MSC application is challenging, due to the many variables that need to be considered. We have designed this study as a prototype analysis, to be used for comparable analysis in other treatment indications, where therapeutic MSCs or other MSC-like products are given to more immunocompetent patients. Patients that have undergone HSCT are strongly immunocompromised. Limited efficacy of MSC treatment due to immunogenic blood groups may be more difficult to document. However, this well characterized patient group could serve as an example, for
maximizing the therapeutic efficacy of these cells in various treatment approaches.

Depending on the therapeutic approach and its underlying limitations, different major choices in manufacturing therapeutic MSCs have to be considered. The most common cell source is cryo-banked third party MSCs cultured for 2–4 passages in media containing FCS. Cell handling directly before infusion is also important, as different centers have developed specific routines for cell washing and infusion [4], affecting cell function [32]. MSCs are often washed and infused in buffer containing supplements such as ABP, HSA and low dose heparin. The suspension medium was shown to influence the interaction of MSCs with endothelium and pulmonary toxicity after infusion [32]. Interpretation of ABO status for HSCT-transplant patients is multifactorial. One needs to consider the original blood group of the HSCT recipient and its possible change after obtaining the HSCT graft, and the impact of HSCT related procedures, such as transfusions, on circulating antibody levels at the time of MSC infusion. Here we present a stepwise analysis on the possible impact of ABO blood groups for the outcome of MSC therapy.

Presence of ABO antigens in native clinical grade MSCs

As outlined earlier, intrinsic antigen expression in native clinical grade MSCs and its change upon encounter of stimulatory or differentiating events in vivo may affect outcome. It has previously been suggested that ABO status is of minor importance for MSC therapy since MSCs do not express or adsorb ABO antigens on their surface [18,19]. Our present study found, that although the ABO promoter region in MSCs is methylated to a similarly low degree as the housekeeping gene GAPDH, the cells do not express ABO transcripts under resting or stimulating conditions. There are many possible explanations for a lack of ABO transcript expression in MSCs, such as repressive histone marks, nuclear localization in repressive nuclear compartments, a lack of transcription factors regulating this particular gene in these particular cells, or possibly the presence of regulatory micro-RNAs. The ABH antigens, carried by four main types of carrier carbohydrate chains, are typically found on erythrocytes, but are also present at high density in epithelial and endothelial cells [33]. For both A and H determinants, branched or un-branched type 2 chains exist, with the unbranched type 2 chain (classical i antigen) being predominant in fetal/newborn cells, while the branched form (classical I antigen) is predominant in adult cells. A recent publication by Hirvonen et al. [34] highlights that particularly umbilical cord blood derived MSCs show “immature” cell-specific expression of the blood group i epitope (linear poly-N-acetyllactosamine chain), which was not found in differentiated cells. Further in-depth studies on the “glycomics” of MSCs may therefore be of interest in “mesenchymal stem cell” phenotyping and to evaluate MSCs differentiation stages [35].
Table 2. HSCT patient ABO antibody titers at the time of MSC infusion.

| MSC Recipient Subject Code | Blood Group HSC R/D | MSC Donor Anti-A IgM/IgG | Anti-B IgM/IgG | Treatment Indication | Clinical Response |
|-----------------------------|---------------------|--------------------------|---------------|---------------------|-------------------|
| 910 M/45                    | AB/A                | O                        | 0/0           | GvHD                | SD                |
| 917 F/61                    | AB/A                | B                        | 0/0           | GvHD                | PD                |
| 1007 M/59                   | AB/A                | A                        | 0/0           | GvHD                | CR                |
| 1071 M/48                   | AB/A                | AB                       | 0/0           | GvHD                | PD                |
| 1068 F/34                   | A/A                 | O                        | 0/0           | GvHD                | PR                |
| 1080 F/56                   | A/A                 | B                        | 0/0           | GvHD                | CR                |
| 1101 M/55                   | A/A                 | AB                       | 0/0           | GvHD                | PD                |
| 1115 M/55                   | A/A                 | O                        | 0/0           | GvHD                | CR                |
| 1139 M/02                   | A/A                 | AB                       | 0/0           | GvHD                | CR                |
| 1311 F/39                   | A/B                 | A                        | 0/0           | GvHD                | CR                |
| 1082 F/64                   | A/O                 | B                        | 0/0           | GvHD                | PR                |
| 1271 M/36                   | A/O                 | A                        | 0/0           | GvHD                | CR                |
| 1048 M/48                   | B/O                 | B                        | 1/8           | GvHD                | PR                |
| 1141 M/65                   | B/O                 | O                        | 0/4           | GvHD                | PD                |
| 1163 M/31                   | O/B                 | A                        | 0/0           | GvHD                | CR                |
| 1084 M/35                   | O/O                 | O                        | 0/4           | GvHD                | PD                |
| 1090 F/01                   | O/O                 | A                        | 0/8           | GvHD                | CR                |
| 1098 M/14                   | O/O                 | A                        | 32/64         | GvHD                | CR                |
| 1131 F/53                   | O/O                 | O                        | 0/4           | GvHD                | PD                |

Abbreviations: MSC, mesenchymal stromal cell; HSC, hematopoietic stem cell; R/D, donor/recipient; Anti-A or anti-B IgM/IgG, agglutination titers of anti blood group antigen A or B antibodies of immunoglobulin M or G type; GvHD, graft versus host disease; and clinical response to MSC treatment expressed as: CR, complete response; PR, partial response; SD, stable disease; and PD, progressive disease.

Table 3. Evaluation ABO-related clinical response to MSCs.

| Patient sex before HSCT: | O | A, B, AB | P-value |
|--------------------------|---|----------|---------|
| Patient sex: male/female | 23/08 | 29/13 | 0.6312 |
| Patient age: median (range) | 42 (1.0 – 65) | 45 (1.0 – 68) | 0.4055 |
| Patient age: children/adults | 11/20 | 09/33 | 0.1832 |
| Indication for MSC treatment: | | | 0.3044 |
| Graft-versus-host disease | 26 | 31 |
| Tissue injury after HSCT | 5 | 11 |
| MSC donor sex: male/female | 24/24 | 29/28 | 0.9286 |
| MSC donor age: median (range) | 37 (24 – 66) | 33 (6.0 – 66) | 0.0637 |
| MSC cell passage: median (range) | 2.6 (1.0 – 4.0) | 2.6 (1.0 – 3.0) | 0.9204 |
| MSC cell dose: median x10^6/kg (range) | 1.7 (0.7 – 4.2) | 1.7 (0.7 – 3.0) | 0.6661 |
| MSC HLA match with recipient: | 07/48 (15%) | 08/57 (14%) | 0.9363 |
| Third party unrelated donor | 41 | 49 |
| HLA-identical sibling or related | 7 | 8 |
| Patient response to treatment: | 33/48 (69%) | 38/57 (67%) | 0.8202 |
| Complete and partial responders | 33 | 38 |
| Stable and progressive disease | 15 | 19 |

Patient characteristics and evaluation of clinical response to individual MSC-infusions in patients undergoing HSCT (Stockholm, n = 70; and Leiden, n = 35 MSC infusions). Blood type O (containing highest titers of both anti-A/B antibodies) was compared to blood type A, B, and AB (blood containing anti-B, anti-A, or no anti-A/B antibodies, respectively). Abbreviations: HSCT, hematopoietic stem cell transplantation; MSC, mesenchymal stromal cell; BG, blood group; HLA, human leukocyte antigen. Statistics: P-value is calculated using Mann-Whitney rank-sum test (for continuous variables), Fisher’s exact t-test (comparing two categorical variables), or Chi²-test (comparing more than two categorical variables).

doi:10.1371/journal.pone.0085040.t003
Contamination of clinical MSCs with ABO antigens from supplements and relevance of ABO status for clinical application of therapeutic MSCs

MSCs show a hypo-immunogenic profile, which allows their transplantation across HLA barriers, although autologous cells can be used in many clinical settings. Importantly, previous studies indicate that the therapeutic efficacy of MSCs could potentially be compromised by immunogenic substances derived from culture supplements used in MSC production, such as xeno-antigens derived from FCS [13]. Spees and coworkers found that 7 to 30 mg of FCS proteins can be incorporated in a typical dose of these cells [100 million cells], but FCS antigen contamination can be reduced to less than 100 ng (100,000-fold reduction) by washing with human serum. Feasible alternatives to FCS, such as pooled human ABS, HPL, and PRP have therefore been established in the past decade [14–17]. Nonetheless, also human substitutes must be handled with care, due to individual differences, such as donor blood group and HLA type, and be prepared accordingly, to minimize any adverse reactions [16]. In agreement with Schäfer et al. [19], we found that MSCs do at best only display minimal amounts of A and B antigens on their surface, after culture in media containing ABS, highlighting the safety of ABS for MSC expansion, although supply is limited due to the scarcity of group AB donors (only less than 5% of blood donors are of AB group). We found no reactivity with anti-A/B antibodies after culture in media containing FCS or PRP, supporting the choice of abundant PRP for expansion of MSCs [14–17]. Importantly, incubation of MSCs with fresh ABP, which is used for washing and cell infusion, lead to a clear dose and time-dependent increase in anti-A/B binding, which did not occur with plasma from group O donors, raising the question if the amount of adsorbed ABO antigen on MSCs surface is sufficient to elicit an adverse whole blood response?

In vitro exposure to blood from immunocompetent blood group O donors, displaying high titers of anti-A/B titers of ABO antibodies [21], lead to an increased triggering of the instant blood mediated inflammatory reaction (IBMIR). Triggering of IBMIR was most evident when using thawed cells resuspended in ABP buffer, as opposed to HSA buffer, strongly advocating for replacement of poorly defined ABP by GMP-compliant HSA, to minimize any unnecessary adverse reactions [7,36]. This is of particular importance when giving MSCs to immunocompetent patient groups, such as in treatment of type-1 diabetes or multiple sclerosis. Could preformed naturally-occurring anti-A/B antibodies have affected MSCs therapeutic efficiency in HSCT patients? These antibodies can potentially mediate graft rejection [8,37]. Particularly patients with higher titers of anti-A/B would be at risk to reject ABO-antigen-contaminated MSCs. It is known from solid organ transplantation that predominantly adult blood group O recipients are a risk group for early allograft rejection, due to the presence of higher levels of anti-A/B IgG antibodies [21]. We generally found only very low agglutination titers of anti-A/B in our patient cohort and no correlation with direct clinical outcome. The conditioning prior to HSCT and prevention and treatment of established GvHD likely account for the low antibody titers and possibly confounds our analysis. When evaluating the clinical outcome with respect to MSC recipients' blood group before or after HSCT (O vs. A, B, and AB) we found a trend for lower response in blood group O recipients. It appears that the quantities of anti-A/B immunoglobulin found in these strongly immunocompromised patients are insufficient to elicit a relevant response towards therapeutic MSCs when used for the treatment of HSCT disorders, such as acute GvHD and hemorrhagic cystitis, but immunocompetent patients could potentially reject MSCs washed with immunogenic ABP.

Conclusion and Summary

MSCs do not inherently express ABO antigens, but can potentially adsorb significant amounts of immunogenic antigens with cross reactivity to anti-A/B from undefined human serum/plasma, used for cell production and infusion, respectively. We here show, that MSCs do not adsorb immunogenic ABO antigens from culture media containing FCS or human substitutes such as ABS and PRP as supplements, but MSC adsorbed antigen from the fresh ABP used for washing and cell infusion. Blood exposure of cells resuspended in buffer containing ABP elicited stronger triggering of IBMIR in vitro. We found a trend for worse clinical outcome in blood group O recipients receiving ABP-exposed MSCs, who displayed higher amounts of circulating ABO antibodies. We therefore suggest exchanging ABP by more defined, non-immunogenic, commercially available HSA, particularly when giving cells to immunocompetent patients, to eliminate this unnecessary factor of uncertainty and to maximize the cell product quality and functionality in vivo.

Supporting Information

Figure S1 ABO antigen surface expression in clinical grade MSCs. Flow cytometry was used to detect the expression of ABH antigens on freshly thawed low-passage clinical grade MSCs. (A) Representative histogram plots for 3 MSCs (Code K7: A-secretor, K25: B-secretor, and K15: O-secretor) labeled with anti-A (left, red line), anti-B (middle, blue), anti-H (right, panel, green), are shown compared to MSCs labeled with secondary antibody only (black line). The median fluorescence intensity (MFI) obtained with respective test labeling (red, green, and blue), or labeling with secondary antibody only (black), is depicted in the histograms, and the relative fluorescence intensity (RFI) was calculated by dividing the MFI of anti-ABH-labeled cells, by the MFI obtained with secondary antibody only. (B) Summary for detection of ABH or paragloboside (PG) carbohydrate antigen on the cell surface of blood type A (black), type B (grey), and type O (white) MSCs. The cells were grouped according to their putative secretor (full symbols) or non-secretor status (shaded symbols), which was determined by FITC (secretor) genotyping, as summarized in Table 1. Data are expressed as RFI and presented as means ± SD.

Figure S2 Potential impact of recipient anti-A/B titers for clinical response. Patient evaluation of responders (CR, complete response, and PR, partial responder) and non-responders (SD, stable disease, and PD, progressive disease) to MSC treatment shows no significant differences when comparing: (A) Agglutination titers of all ABO antibodies (combining Anti-A + Anti-B, and IgG + IgM; P = 0.3134), or (B) Agglutination titers of ABO antibodies separating anti-A/B immunoglobulin G (IgG; P = 0.2514) and IgM (P = 0.6036).

Table S1 Antibodies and reagents used for immuno-staining.

Table S2 Evaluation ABO-related clinical response to ABP-exposed MSCs. Patient characteristics and evaluation of clinical response to ABP-exposed MSCs. Blood type O (containing highest titers of both anti-A/B antibodies) was compared to blood
type A, B, and AB (anti-B, anti-A, or no anti-A/B antibodies, respectively). Abbreviations: HSCT, hematopoietic stem cell transplantation; MSC, mesenchymal stromal cell; BG, blood group; HLA, human leukocyte antigen. Statistics: P-value is calculated using Mann-Whitney rank-sum test (for continuous variables), Fisher's exact t-test (for comparing two categorical variables), or Chi2 test (comparing more than two categorical variables).

Reference
1. Singr NG, Caplan AI (2011) Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 6: 457–478.
2. Ankeny J, Karp JM (2010) Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16: 203–209.
3. Galipeau J (2013) The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15: 2–8.
4. Phimney DG, Senehe L (2013) Mesenchymal stromal cells misconceptions and evolving concepts. Cytotherapy 15: 140–145.
5. Le Blanc K, Frassoni F, Ball L, Locatelli F, Rodolli H, et al. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579–1586.
6. von Bahr L, Sundberg B, Lonnies L, Sander B, Karbach H, et al. (2012) Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 18: 557–564.
7. Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgve G, et al. (2012) Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 30: 1563–1574.
8. Gahil U (2006) Xenotransplantation and ABO incompatible transplantation: the similarities they share. Transfus Apher Sci 35: 43–58.
9. Storry JR, Olson ML (2009) The ABO blood group system revisited: a review and update. Immunohematology 25: 48–59.
10. Bianco-Miotto T, Hussey DJ, Day TK, O’Keeffe DS, Dobrovic A (2009) DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS ONE 4: e7170.
11. Orntoft TF, Meldgaard P, Pedersen B, Wolf H (1996) The blood group ABO gene transcript is down-regulated in human bladder tumors and growth-stimulated urothelial cell lines. Cancer Res 56: 1031–1036.
12. Olson ML, Irshaid NM, Hosseini-Maaf B, Hellberg A, Moulds MK, et al. (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733–1738.
13. Spees JL, Gregory CA, Singh H, Tuckier HA, Peister A, et al. (2004) Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 9: 747–756.
14. Kocaomer A, Kern S, Kluter H, Bieback K (2007) Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from bone marrow. Stem Cells 25: 1270–1278.
15. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, et al. (2009) Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27: 2331–2341.
16. Schallmoser K, Strunk D (2013) Generation of a pool of human platelet lysate and efficient use in cell culture. Methods Mol Biol 946: 349–362.
17. Feinzer N, Gadelorge M, Furst D, Maurer C, Dussend J, et al. (2012) Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production, content and identification of active components. Cytotherapy 14: 540–554.
18. Sundin M, Ringden O, Sundberg B, Nava S, Goetherstrom C, et al. (2007) No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92: 1208–1215.
19. Schafer R, Schnaitt M, Klaffschenkel RA, Siegel G, Schule M, et al. (2011) Expression of blood group genes by mesenchymal stem cells. Br J Haematol 153: 520–528.
20. Horvitz EM, Gordon PL, Koo WK, Mars JC, Neel MD, et al. (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 99: 8932–8937.
21. Toki D, Ishida H, Horita S, Yamaguchi Y, Tanabe K (2009) Blood group O recipients associated with early graft deterioration in ABO-incompatible kidney transplantation. Transplantation 88: 1196–1199.
22. Rincken D, Leblanc K (2011) Pooled MSCs for treatment of severe hemorrhage. Bone Marrow Transplant 46: 1158–1160.
23. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Rincken O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57: 11–20.
24. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, et al. (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733–1738.
25. Hosseini-Maaf B, Hellberg A, Chester MA, Olson ML (2007) An extensive polymerase chain reaction-allele-specific polymorphism strategy for clinical ABO blood group genotyping that avoids potential errors caused by null, subgroup, and hybrid alleles. Transfusion 47: 2110–2125.
26. Olsson ML, Chester MA (1995) A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Vox Sang 69: 242–247.
27. Connolly-Andersen AM, Moll G, Anderson C, Akerstrom S, Karlberg H, et al. (2011) Cirrhmatic-Congo hemorrhagic fever virus activates endothelial cells. J Virol 85: 7766–7774.
28. Liu QP, Sudzenderb G, Yuan H, Bennett EP, Pietz G, et al. (2007) Bacterial glycosidases for the production of universal red blood cells. Nat Biotechnol 25: 454–464.
29. Nilsson B, Larsson R, Hong J, Elgve G, Ekdahl KN, et al. (1998) Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 92: 1661–1667.
30. Bennet W, Sundberg B, Grotth OG, Brendel MD, Brandhorst D, et al. (1999) Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 48: 1907–1914.
31. Gustafson EL, Elgve G, Hughes RD, Mitry RR, Sanchez J, et al. (2011) The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation 91: 632–638.
32. Deak E, Ruster B, Keller L, Eckert K, Fichtner I, et al. (2010) Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 12: 260–264.
33. Hakomori S (1999) Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1473: 247–266.
34. Hirvonen T, Suila H, Kotovuori A, Ritamo I, Heiskanen A, et al. (2012) The i antigen in human islets: a finding with implications for clinical intraportal islet transplantation? Diabetes 61: 1136–1142.
35. Nilsson B, Korsgren O, Lambris JD, Ekdahl KN (2010) Can cells and antibodies address the immune rejection of bone marrow transplanted islets of Langerhans? Swiss Med Wkly 137 Suppl 155: 101–113.
36. Stuss G, Mueller RJ, Passweg J, Schanz U, Rieben R, et al. (2007) ABO blood group incompatible haematopoietic stem cell transplantation and xenograft rejection. Swiss Med Wkly 137 Suppl 155: 1018–1018.